Non-invasive tubulointerstitial damage markers may allow better titration and monitoring of renoprotective therapy. We investigated the value of urinary vitamin D binding protein excretion (uVDBP) as a tubulointerstitial inflammation and fibrosis marker in adriamycin rats, and tested whether uVDBP parallels renal damage and responds to therapy intensification in humans. In adriamycin (ADR) rats, uVDBP was strongly elevated vs controls (CON) already 6 wks after nephrosis induction (ADR: 727±674 [mean±SD] vs CON: 9±12 µg/d, p<0.01), i.e. before onset of pre-fibrotic and inflammatory tubulointerstitial damage, and at all following 6-wk time points until end of follow up at 30 wks (ADR: 1403±1026 vs CON: 206±132 µg/d, p<0.01). In multivariate regression analysis, uVDBP was associated with tubulointerstitial macrophage accumulation (standardized betaâ=â0.47, pâ=â0.01) and collagen III expression (standardized betaâ=â0.44, pâ=â0.02) independently of albuminuria. In humans, uVDBP was increased in 100 microalbuminuric subjects (44±93 µg/d) and in 47 CKD patients with overt proteinuria (9.2±13.0 mg/d) compared to 100 normoalbuminuric subjects (12±12 µg/d, p<0.001). In CKD patients, uVDBP responded to intensification of renoprotective therapy (ACEi+liberal sodium: 9.2±13.0 mg/d vs dual RAAS blockade+low sodium: 2747±4013, p<0.001), but remained still >100-fold increased during maximal therapy vs normoalbuminurics (p<0.001), consistent with persisting tubulointerstitial damage. UVDBP was associated with tubular and inflammatory damage markers KIM-1 (standardized betaâ=â0.52, p<0.001), beta-2-microglobuline (st.betaâ=â0.45, p<0.001), cystatin C (st.betaâ=â0.40, p<0.001), MCP-1 (st.betaâ=â0.31, p<0.001) and NGAL (st.betaâ=â0.20, pâ=â0.005), independently of albuminuria. UVDBP may be a novel urinary biomarker of tubulointerstitial damage. Prospectively designed studies are required to validate our findings and confirm its relevance in the clinical setting.
Urinary vitamin D binding protein: a potential novel marker of renal interstitial inflammation and fibrosis.
阅读:3
作者:MirkoviÄ Katarina, Doorenbos Carolina R C, Dam Wendy A, Lambers Heerspink Hiddo J, Slagman Maartje C J, Nauta Ferdau L, Kramer Andrea B, Gansevoort Ronald T, van den Born Jacob, Navis Gerjan, de Borst Martin H
| 期刊: | PLoS One | 影响因子: | 2.600 |
| 时间: | 2013 | 起止号: | 2013;8(2):e55887 |
| doi: | 10.1371/journal.pone.0055887 | ||
特别声明
1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。
2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。
3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。
4、投稿及合作请联系:info@biocloudy.com。
